Human Genome Sciences Inc (HGSI): Today's Featured Health Care Loser

Human Genome ( HGSI) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 0.9%. By the end of trading, Human Genome fell 8 cents (-0.6%) to $13.38 on light volume. Throughout the day, 2.8 million shares of Human Genome exchanged hands as compared to its average daily volume of 7.6 million shares. The stock ranged in price between $13.35-$13.60 after having opened the day at $13.38 as compared to the previous trading day's close of $13.46. Other company's within the Health Care sector that declined today were: Aoxing Pharmaceutical Company ( AXN), down 13.1%, Cleveland BioLabs ( CBLI), down 13%, Graymark Healthcare ( GRMH), down 12.6%, and Achillion Pharmaceuticals ( ACHN), down 9.6%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.7 billion and is part of the drugs industry. Shares are up 82.1% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Human Genome a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Human Genome as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

On the positive front, Amyris ( AMRS), up 27.5%, Marshall Edwards ( MSHL), up 19.6%, American Caresource Holdings ( ANCI), up 15.6%, and Tengion ( TNGN), up 13.8%, were all gainers within the health care sector with Aetna ( AET) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Stock Futures Waver as Earnings Season Begins

Stocks to Watch: WellPoint, Amerigroup, Alcoa (Update 1)

5 Things You Should Know Before the Stock Market Opens

Celgene Not Buying Human Genome Sciences

Human Genome Sciences Inc (HGSI): Today's Featured Health Care Winner